comparemela.com

Latest Breaking News On - Istituto romagnolo - Page 1 : comparemela.com

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
Madrid
Spain
Zurich
Züsz
Switzerland
Texas
United-states
Abigail-linehan
Istituto-nazionale-tumori

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
Switzerland
Italy
Turkey
Dino-amadori
Daniele-calistri
Istituto-romagnolo
Kevin-puylaert
Bioscience-laboratory
Instagram

Age No Barrier to Preserved QoL, Functional Recovery After Surgery for CRC

More than 70% of patients with a median age of 79 achieved both outcomes at 3-6 months

Meldola
Emilia-romagna
Italy
New-york
United-states
University-of-rochester
Charles-bankhead
Istituto-romagnolo
Anthony-loria
Fergalj-fleming
Flavia-foca
Tumori-dino-amadori

Significant EU funding for implementing value-based cancer care at European cancer hospitals

The EU has awarded 7 MEUR to HUS Helsinki University Hospital led Consortium, which aims to unlock the full potential of real-world data collected in European cancer hospitals. This in turn will support the implementation of safer, more efficient, and personalized novel cancer therapies. “To implement value-based cancer care, real-world data on the cost-effectiveness of treatments is needed in real-time”, states the project lead, senior medical director in oncology, Johanna Mattson.

Helsinki
Eteläuomen-läi
Finland
Istituto-romagnolo
Tumori-dino-amadori
Nederlands-kanker-instituut-anton
Rigshospitalet-copenhagen-university-hospital
Bc-platforms
Helsinki-university-hospital
University-hospital
Stichting-het-nederlands-kanker-instituut-anton
Siemens-healthcare

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC ( Optimizing In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ponatinib (Iclusig ) over a range of three starting doses (45mg, 30mg, 15mg) followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to prior tyrosine kinase inhibitor (TKI) therapy met its primary endpoint.

Switzerland
Norway
United-states
United-kingdom
Israel
Delaware
Russia
Turkey
American
Rachael-remaly-franco
Luca-marini
Istituto-romagnolo

vimarsana © 2020. All Rights Reserved.